Daiichi Sankyo to Return Exclusive Development and Commercialization Rights for Four Diagnostic Imaging Agents to GE Healthcare in Japan

 Daiichi Sankyo to Return Exclusive Development and Commercialization Rights for Four Diagnostic Imaging Agents to GE Healthcare in Japan

Daiichi Sankyo to Return Exclusive Development and Commercialization Rights for Four Diagnostic Imaging Agents to GE Healthcare in Japan

Shots:

  • Daiichi to return rights for four diagnostic imaging agents to GE Healthcare Omnipaque, Omniscan, including Visipaque, Sonazoid and the transfer of marketing authorization rights is expected to be complete in Mar’2020
  • GE Healthcare will be responsible for commercialization & regulatory activities for all four imaging agents. Daiichi will hold the rights to distribute the products till Mar’2022 and later transfer the rights to GE Healthcare
  • Omnipaque (Iohexol) is a contrast agent used in X-rays to visualize arteries, veins, ventricles of the brain, the urinary system & joints. Omniscan is a gadolinium-based contrast agent used in MRI to visualize lesions with abnormal vascularity. Sonazoid & Visipaque are the contrasting agent for ultrasonography and CT scans respectively

 Click here to read full press release/ article | Ref: Daiichi Sankyo | Image: Logos

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post